-
Drug Ming Juno, a leader in cell immunotherapy, is listed on the main board of the Hong Kong Stock Exchange
Time of Update: 2021-03-07
The company has established an integrated platform dedicated to the development, manufacture and commercialization of breakthrough cell immunotherapy for blood and solid tumors.
-
Beida Pharmaceuticals is going to the Hong Kong Stock Exchange to list, and two more anti-cancer
Time of Update: 2021-03-04
cancer, ensartinib, in the second decade. this is a new powerful, highly selective new generation of APK inhibitors, by effectively inhibiting the activity of APK, to inhibit tumor growth. 2020, Nsatinib was approved for listing in China
-
The second batch of volume purchase lists flowed out of generic drugs to kill prices or more violently
Time of Update: 2021-03-04
/> As a result of this news, on November 29th, the share prices of Stone Pharmaceutical Group, Green Leaf Pharmaceuticals, Hengrui Pharmaceuticals and other related pharmaceutical companies fell sharply. "From the current information
-
The four sub-centers of the State Drug Administration are listed
Time of Update: 2021-03-02
and the Medical Device Technical Review and Inspection Dawan Division Center were officially established in Shenzhen, which is a concrete action to implement the spirit of General Secretary Xi Jinping's important speech, and is an important initiative
-
Stone Pharmaceutical Group's application for the listing of anticancer drugs is to be included in the priority review
Time of Update: 2021-03-02
lipid body is the self-developed mitoxyquinone lipid system agent, is a 2.2 class of improved new drugs, stone pharmaceutical group has full intellectual property rights. In 2017, the FDA granted the drug orphan status for the treatment of external T
-
Beda Pharmaceuticals listed two years of continuous decline in performance, trapped in the "one drug, one big" dilemma?
Time of Update: 2021-02-27
that this downward trend from 2017 to date. third-quarter results showed that Bayda Pharmaceuticals reported revenue of 928 million yuan in the first three quarters, up 20.74 percent from a year earlier, while net profit attributable
-
GlaxoSmithKline remains a leader in obtaining a list of drugs
Time of Update: 2021-02-26
GlaxoSmithKline maintains its highest position on the global list of pharmaceutical companies, dedicated to providing medicines, vaccines and diagnostics to people in low- and middle-income countries. 's Access to Medicines Index for 2018
-
Officially implemented from March 1st! There are new changes in the list of medical insurance drugs in Hebei Province
Time of Update: 2021-02-24
, 167 kinds of supplemental drugs containing Western medicine and 130 kinds of Chinese medicine were retained in Hebei Province. , there are 892 Chinese medicine tablets that the fund can pay for. Drug Catalog is the standard
-
A batch of medical devices named by the State Drug Administration (attached list)
Time of Update: 2021-02-24
Pharmaceutical Network February 20, these medical devices, the first in China on February 18, according to the Official Website of the State Council, the State Drug Administration issued the "2020 Medical Device Registration Report." the above
-
Genfit's double agonist was awarded orphan drug status by the FDA and EMA
Time of Update: 2021-02-24
Genfit plans to launch Phase III clinical studies in 2019 to further evaluate the efficacy and safety of elafibranor's treatment of PBC.
-
Jiangsu Province not listed products without national medical insurance drug code will not be able to declare sunshine procurement
Time of Update: 2021-02-24
april 1, 2021, the national medical insurance drug classification and code published by the provincial platform network products will be displayed in the drug settlement trading system for the transaction subject to be compared.
-
Drug enterprise risk warning issued 33 pharmaceutical companies on the list!
Time of Update: 2021-02-24
2, Shandong Weizhi Encycloddic Pharmaceutical Co., Ltd. the company produced hydrochloric acid Lidokain injection, "check" item "visible foreign body" does not meet the standard provisions, Shandong Provincial Drug Administration issued a decision on administrative punishment, fined about 495,000 yuan.
-
Cancer is the first innovative drug! Ono Pharmaceuticals filed a listing application for NON-7643 in Japan
Time of Update: 2021-02-17
Ono Pharmaceuticals of Japan recently announced that it has filed a listing application for ONO-7643, a gastric hunger agent (ghrelin) permutation agent used to improve weight loss and anorexia in patients with cancer.
-
Responsitable pediatric epilepsy new drug! Aquestive's drug Sympazan is listed in the U.S. as the first chlorpyrine mouth:
Time of Update: 2021-02-17
since it was approved by the FDA in 2011, chlorpyrine tablets and oral suspension (brand name: Onfi) have been trusted complementary therapies for the LGS patient population.
-
First oral CGRP-subject antagonist migraine drug! El Jian ubrogepant will submit a listing application in early 2019:
Time of Update: 2021-02-14
Allergan recently announced that it has completed two clinical studies of ubrogepant for acute migraine treatment and has obtained positive safety and tolerance data. first study (UBR-MD-04) assessed the long-term safety and tolerance
-
2 imported new drugs to submit a listing application! From Amjin, Bayer
Time of Update: 2021-02-14
January 14 this year, Bayer announced that the FDA had accepted Finerenone's NDA application and granted it priority review eligibility for the treatment of patients with chronic kidney disease (CKD) with type 2 diabetes (T2D).
-
A list of the costs of four types of drugs will be made from time to time
Time of Update: 2021-02-13
specific deployment to the investigation of the production cost of price-varying drugs to be carried out in the province from now on. "Notice" clearly, the scope of cost investigation will cover the following four types
-
The listing application for Luspatercept, an innovative drug for blood diseases, was reviewed as a priority by CDE
Time of Update: 2021-02-12
On February 4, 2021, Shishi Meishiguibao China announced that its red blood cell maturant Luspatercept (English product name Reblozyl Chinese Chinese; The listing application for Liblotzer has been formally accepted by the Drug Review Center (CDE
-
Jiangsu these 10 batches of unqualified food on the black list, involving food additives, agricultural and veterinary drug residues and other issues
Time of Update: 2021-02-11
shall not be detected: Yujiang City Yanghe Town Alcohol Grain brewing Co., Ltd.; Address: / Dongtai New Cooperative Trading Chain Co., Ltd. Tainan Supermarket Dongtai Town, Helun Road 4 (crossroads) red sorghum wine 45% vol, 2L / barrel dream
-
Olapali's new adaptive drug listing application is to be included in the priority review for the treatment of prostate cancer
Time of Update: 2021-02-11
On January 21, CDE's official website showed that AstraZeneca's application for the listing of new indications for the Olapali tablet was to be included in the priority review, a single drug used to treat adult patients with BRCA1/2 mutations
